Federal Circuit Rules For Apotex In Paxil Patent Suit

Law360, New York (April 26, 2004, 12:00 AM EDT) -- In a blow to U.K. drug maker GlaxoSmithKline, the U.S. Court of Appeals for the Federal Circuit has rejected a key claim for the U.S. patent covering Paxil (paroxetine hydrochloride), the world’s top-selling antidepressant.

Glaxo had sued Canadian generic maker Apotex, the first company to challenge the validity of patents covering Paxil and the first to gain approval from the U.S. Food and Drug Administration for a generic version of the drug.

Paxil is the leading antidepressant drug on the market with annual worldwide sales totaling...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.